logo
Deadline Soon: MicroStrategy Incorporated (MSTR) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Deadline Soon: MicroStrategy Incorporated (MSTR) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

Business Wire10-07-2025
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz reminds investors of the upcoming July 15, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired MicroStrategy Incorporated d/b/a Strategy ('Strategy' or the 'Company') (NASDAQ: MSTR) securities between , inclusive (the 'Class Period').
IF YOU ARE AN INVESTOR WHO LOST MONEY ON MICROSTRATEGY INCORPORATED (MSTR), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT.
What Happened?
On April 7, 2025, Strategy disclosed that, following its adoption of Accounting Standards Update No. 2023-08 ('ASU 2023-08'), which requires publicly traded companies to measure their crypto assets at fair value in their financial statements, it recognized a $5.91 billion unrealized loss on its digital assets for the first quarter 2025. The Company warned that it 'may not be able to regain profitability in future periods, particularly if [it] incur[s] significant unrealized losses related to [its] digital assets.'
On this news, Strategy's stock price fell $25.47, or 8.7%, to close at $268.14 per share on April 7, 2025, thereby injuring investors.
Then, on May 1, 2025, Strategy released its first quarter 2025 financial results, confirming that it had recorded an unrealized fair value loss on digital assets of approximately $5.9 billion due to applying a fair value accounting methodology to Strategy's bitcoin assets following bitcoin's depreciation in value during the first quarter of 2025.
What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the anticipated profitability of the Company's bitcoin-focused investment strategy and treasury operations was overstated; (2) the various risks associated with bitcoin's volatility and the magnitude of losses Strategy could recognize on the value of its digital assets following its adoption of ASU 2023-08 were understated; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
If you purchased or otherwise acquired MicroStrategy securities between April 30, 2024 and April 4, 2025, the deadline to seek appointment as the lead plaintiff in the securities fraud class action is July 15, 2025.
Contact Us To Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact us:
Frank R. Cruz
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Email us at: info@frankcruzlaw.com
Call us at: 310-914-5007
Visit our website at www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW
If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

LGI Homes (NASDAQ:LGIH) sheds US$96m, company earnings and investor returns have been trending downwards for past five years
LGI Homes (NASDAQ:LGIH) sheds US$96m, company earnings and investor returns have been trending downwards for past five years

Yahoo

time21 minutes ago

  • Yahoo

LGI Homes (NASDAQ:LGIH) sheds US$96m, company earnings and investor returns have been trending downwards for past five years

Generally speaking long term investing is the way to go. But unfortunately, some companies simply don't succeed. For example the LGI Homes, Inc. (NASDAQ:LGIH) share price dropped 55% over five years. That's an unpleasant experience for long term holders. And some of the more recent buyers are probably worried, too, with the stock falling 51% in the last year. If the past week is anything to go by, investor sentiment for LGI Homes isn't positive, so let's see if there's a mismatch between fundamentals and the share price. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. Looking back five years, both LGI Homes' share price and EPS declined; the latter at a rate of 1.7% per year. This reduction in EPS is less than the 15% annual reduction in the share price. This implies that the market was previously too optimistic about the stock. The low P/E ratio of 6.50 further reflects this reticence. You can see how EPS has changed over time in the image below (click on the chart to see the exact values). It's probably worth noting that the CEO is paid less than the median at similar sized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here.. A Different Perspective While the broader market gained around 16% in the last year, LGI Homes shareholders lost 51%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 9% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand LGI Homes better, we need to consider many other factors. For example, we've discovered 1 warning sign for LGI Homes that you should be aware of before investing here. For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio

Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner

Yahoo

time24 minutes ago

  • Yahoo

Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner

Key Points Exelixis' most important product should continue driving strong financial results through the end of the decade. The oncology specialist is working on a next-gen medicine that could be even better than its crown jewel. The midcap biotech looks well-positioned to deliver market-beating returns over the long run. 10 stocks we like better than Exelixis › A decade ago, shares of Exelixis (NASDAQ: EXEL), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45 apiece. In other words, Exelixis has crushed the market since 2015. Some might think there is little upside left for the stock after this run, but that's not the case. Read on to find out why Exelixis still has plenty of growth fuel left in the tank. Cabometyx is still doing the heavy lifting Exelixis is best known for its cancer medicine, Cabometyx. First approved in the U.S. in 2016 for patients with renal cell carcinoma (RCC, a form of kidney cancer), it was a bit of a breakthrough as the first therapy to show significant improvements for RCC patients in three important measures: overall survival, progression-free survival, and objective response rate (the percentage of patients who respond to treatment). Cabometyx has since earned numerous label expansions, and it continues to help drive solid top- and bottom-line growth for Exelixis. In the first quarter, the company's revenue jumped by 30.6% year over year to $555.4 million. The company's adjusted earnings per share (EPS) more than tripled to $0.62. Cabometyx has proven to be a successful pipeline drug, becoming the most prescribed tyrosine kinase inhibitor (a type of cancer drug that targets and kills cancer cells) among RCC patients, while making headway in hepatocellular carcinoma (liver cancer) and other markets. Despite Cabometyx's success, though, Exelixis will need more to continue delivering above-average returns over the long run. Generic competition for the medicine is expected to enter the U.S. market by 2030. Thankfully, Exelixis is already preparing for that eventuality. The next stage of growth Exelixis aims to apply the same blueprint that has made it successful over the past decade: developing a cancer medicine that can become a standard of care in a niche with a high unmet need, while earning label expansions in many other markets. The company appears to have already discovered its next gem. Exelixis recently reported positive top-line phase 3 results for zanzalintinib in patients with metastatic colorectal cancer (CRC). Despite having a high 5-year survival rate when caught early, CRC is the second-leading cause of cancer death worldwide partly because, once it has metastasized, there are few effective treatment options. Exelixis is looking to change that with zanzalintinib, and the company's apparent phase 3 success suggests it might be able to pull it off. Furthermore, zanzalintinib is being investigated across other indications, including those where Cabometyx is dominant, such as RCC. The former seems to have a better safety profile than its predecessor, among several other advantages. Beyond RCC and CRC, Exelixis plans to start several other late-stage studies for its next crown jewel this year, all of which will test it against current standards of care. As they say, to be the best, you have to beat the best. That's what Exelixis aims to do with zanzalintinib. Exelixis expects zanzalintinib to generate about $5 billion in sales eventually, far exceeding Cabometyx's current total or, for that matter, Exelixis' annual revenue. There is still some work to be done to get there, but early signs suggest that zanzalintinib is an excellent candidate. Exelixis' recent clinical progress also reinforces its leadership in oncology. The biotech company has several other early-stage candidates in development that could help it move beyond Cabometyx once it starts facing generic competition. Can Exelixis get to $200? From its current stock price of approximately $45, Exelixis needs a compound annual growth rate (CAGR) of at least 16.1% to reach $200 within the next decade and 10.5% to achieve this in 15 years. The former goal is ambitious, but the stock has delivered even better returns than that over the past decade. Although the past is no guarantee of future success, Exelixis' MO has remained the same and could, once again, allow it to generate monster returns over the long run as it makes significant clinical and regulatory progress with zanzalintinib and other pipeline candidates. Even if it falls short of this goal, though, my view is that Exelixis is well-positioned to deliver market-beating returns to patient investors -- the 15-year path to $200 would still be impressive. Either way, the stock looks like a buy. Should you invest $1,000 in Exelixis right now? Before you buy stock in Exelixis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Exelixis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has positions in Exelixis. The Motley Fool has positions in and recommends Exelixis. The Motley Fool has a disclosure policy. Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

After earnings fell by $300 million, Cardinal Health's CEO went ‘ruthless' to turn it around—and he says workers backed him because ‘people want to win'
After earnings fell by $300 million, Cardinal Health's CEO went ‘ruthless' to turn it around—and he says workers backed him because ‘people want to win'

Yahoo

timean hour ago

  • Yahoo

After earnings fell by $300 million, Cardinal Health's CEO went ‘ruthless' to turn it around—and he says workers backed him because ‘people want to win'

Cardinal Health's CEO says 'ruthless prioritization' was needed to turn around the Fortune 500 company whose earnings plummeted $300 million just three years ago. The Gen X chief executive, Jason Hollar, slashed business segments, slimmed down the company and didn't shy away from ruffling feathers with his new reports. But instead of revolting, he reveals they actually embraced the changes: 'People want to win.' Cardinal Health is one of the largest healthcare giants in America, supplying medical products and data solutions for over 90% of U.S. hospitals. But just a few years ago, its operating earnings plummeted $300 million as some segments struggled. When Jason Hollar took over as CEO of the Fortune 500 company in late 2022, the business turnaround required some serious tough love. 'This concept of relentless simplification and ruthless prioritization was the cornerstone of the change management and the strategy,' Hollar tells Fortune. 'And I use the word ruthless for a very particular reason, to put a little bit of an edge to it, because I didn't want people just to reprioritize everything they're doing. I wanted them to stop doing certain things.' Before Hollar took the reins, certain segments were costing the $38 billion health care company hundreds of millions of dollars each year. Cardinal Health's non-GAAP operating earnings fell 12% from $2.3 billion in 2021 to $2 billion in 2022, while non-GAAP net earnings plummeted 13% from $1.6 billion to $1.4 billion in the same time frame. So on his first day as chief executive, Hollar laid out a cutthroat game plan to bring Cardinal Health back to its former glory, including slashing business segments and slimming down the company. And so far, it's worked—the business' operating earnings for Q3 of the 2025 fiscal year hit $730 million. Usually ruffling feathers is a major concern of incoming chiefs. But perhaps surprisingly, Hollar says that Cardinal Health's staff weren't just on board—they were itching for an overhaul. '[Cardinal Health] is a great place to work. But [employees] were getting frustrated as well that we weren't succeeding,' Hollar says. 'It's great to be with a great group of people, but people want to win, and we weren't winning as much as we could have.' Hollar's first days in office: slashing segments and halting M&A It's no easy feat to turn around a heritage company like Cardinal Health that's been operating for nearly 55 years. But Hollar's 'ruthless' approach was the juice the healthcare business needed to get back on track. The 52-year-old executive first joined the Fortune 500 business as CFO in the thick of COVID, when the business was reeling from uncertainty around those pandemic-era changes and product liabilities like opioids. The company had a large balance sheet restructuring, and some recent acquisitions from prior leadership were driving operational challenges. Two years later as CEO, he had the extensive knowledge base to turn things around quickly—so he exited product lines, pulled Cardinal Health out of a 'significant number' of countries, and sold off its non-healthcare portfolio. 'There were a lot of changes done in a pretty short period of time,' Hollar explains. 'I saw that some poor decisions on capital deployment was a primary driver of some of those operating challenges. So I believed if we did fewer things, [if] we simplified the operations in the organization, and then took those resources and reprioritized it to the faster-growing parts of the industry in the business, that we could be a lot more successful.' Cardinal Health's Medical segment, which manufactures surgical and laboratory products, also needed a complete revamp—it had lost $16 million in just one quarter, prior to Hollar stepping in. The CEO also increased its capital expenditures and selling, general, and administrative expenses (S&GA) in speciality growth initiatives. Simultaneously, Hollar streamlined Cardinal Health's focus. During his first 18 months, he didn't pursue any significant M&A, and instead put all his energy into existing products and clients. The business later acquired Specialty Networks in 2024 for $1.2 billion. 'It was an absolute pivot from where we were. We were trying to grow in so many different ways. We were not doing any of them really well,' Hollar says. 'Our service levels improved dramatically, our productivity, our efficiency, and even things like safety and quality are at much better levels. My philosophy is that you can't just do some of the processes better some of the time—all [are] deep-rooted success across the board…or you don't do any of them well.' Not changing the culture, but finally putting in the elbow grease so all workers 'win' It wasn't just the more technical side of Cardinal Health that needed a facelift—Hollar says employees were happy to work there, but were a bit dejected by recent losses. To build up morale and finally get workers on the 'winning' side of things, Hollar delivered an honest truth. 'I told the team, 'There's one value we don't show up with every single day, and that's accountability. That's the one we have to work on,'' Hollar says. 'We're not going to change the values, we're not going to change our mission and vision. What we need to do is we actually just need to live up to them.' Hollar says he knew exactly what leadership shake-up would help him achieve his mission. He separated three of his eight direct reports, eliminating two of the roles entirely. By restructuring the business, he was able to add another three direct reports. Hollar was changing up his personnel, and moving fast—which he says proved to employees that his dedication was stronger than just platitudes. '[I] demonstrated to the team that these are a lot more than happy words, these are our actual actions, that we're going to put resources behind the strategy that I laid out,' Hollar says. 'Ultimately that led to $5 billion of M&A that we've done over just the last 18 months.' This story was originally featured on Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store